82 related articles for article (PubMed ID: 15464392)
21. Development of acetylated HDD kit for preparation of 188Re-HDD/lipiodol.
Lee YS; Jeong JM; Kim YJ; Chang YS; Lee HJ; Son M; Lee JW; Yoon HS; Kang WJ; Lee DS; Chung JK; Lee MC; Suh YG
Appl Radiat Isot; 2007 Jan; 65(1):64-9. PubMed ID: 17010628
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a negatively charged substituent bearing acylation agent.
Shankar S; Vaidyanathan G; Affleck DJ; Peixoto K; Bigner DD; Zalutsky MR
Nucl Med Biol; 2004 Oct; 31(7):909-19. PubMed ID: 15464393
[TBL] [Abstract][Full Text] [Related]
23. Estimated human absorbed dose of ¹⁷⁷Lu-BPAMD based on mice data: Comparison with ¹⁷⁷Lu-EDTMP.
Yousefnia H; Zolghadri S; Shanehsazzadeh S
Appl Radiat Isot; 2015 Oct; 104():128-35. PubMed ID: 26163291
[TBL] [Abstract][Full Text] [Related]
24. (170)Tm-EDTMP: a potential cost-effective alternative to (89)SrCl(2) for bone pain palliation.
Das T; Chakraborty S; Sarma HD; Tandon P; Banerjee S; Venkatesh M; Pillai MR
Nucl Med Biol; 2009 Jul; 36(5):561-8. PubMed ID: 19520297
[TBL] [Abstract][Full Text] [Related]
25. Labeling conditions, in vitro properties and biodistributions of various Sn-labeled complexes.
Yang Y; Luo S; Pu M; Wang W; Wang G; He J; Liu G; Bing W; Wei H
Appl Radiat Isot; 2005 Apr; 62(4):597-603. PubMed ID: 15701415
[TBL] [Abstract][Full Text] [Related]
26. Advantage of 188Re-radiopharmaceuticals in hepatocellular cancer and liver metastases.
Liepe K; Kotzerke J; Lambert B
J Nucl Med; 2005 Aug; 46(8):1407-8; author reply 1407-8. PubMed ID: 16085601
[No Abstract] [Full Text] [Related]
27. Samarium-153 therapy for prostate cancer: the evaluation of urine activity, staff exposure and dose rate from patients.
Parlak Y; Gumuser G; Sayit E
Radiat Prot Dosimetry; 2015 Mar; 163(4):468-72. PubMed ID: 25063786
[TBL] [Abstract][Full Text] [Related]
28. Preparation and characterization of a DOTA-lysine-biotin conjugate as an effector molecule for pretargeted radionuclide therapy.
Hainsworth J; Harrison P; Mather SJ
Bioconjug Chem; 2005; 16(6):1468-74. PubMed ID: 16287243
[TBL] [Abstract][Full Text] [Related]
29. Targeted alpha therapy with 227Th-trastuzumab of intraperitoneal ovarian cancer in nude mice.
Heyerdahl H; Abbas N; Sponheim K; Mollatt C; Bruland Ø; Dahle J
Curr Radiopharm; 2013 Jun; 6(2):106-16. PubMed ID: 23551111
[TBL] [Abstract][Full Text] [Related]
30. Internal dosimetry studies of
Shirmardi SP; Saniei E; Das T; Noorvand M; Erfani M; Bagheri R
Appl Radiat Isot; 2020 Dec; 166():109396. PubMed ID: 32889376
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of a freeze-dried kit for EDTMP-based bone-seeking radiopharmaceuticals.
Garnuszek P; Pawlak D; Licińska I; Kamińska A
Appl Radiat Isot; 2003 Apr; 58(4):481-8. PubMed ID: 12672628
[TBL] [Abstract][Full Text] [Related]
32. Skeletal localization of samarium-153 chelates: potential therapeutic bone agents.
Goeckeler WF; Edwards B; Volkert WA; Holmes RA; Simon J; Wilson D
J Nucl Med; 1987 Apr; 28(4):495-504. PubMed ID: 3572535
[TBL] [Abstract][Full Text] [Related]
33. Preparation and preliminary biological evaluation of a novel 109Pd labeled porphyrin derivative for possible use in targeted tumor therapy.
Chakraborty S; Das T; Banerjee S; Sarma HD; Venkatesh M
Q J Nucl Med Mol Imaging; 2007 Mar; 51(1):16-23. PubMed ID: 17372569
[TBL] [Abstract][Full Text] [Related]
34. Binding studies of [(18)F]-fluoride and polyphosphonates radiolabelled with [(111)In], [(99m)Tc], [(153)Sm], and [(188)Re] on bone compartments: a new model for the pre vivo evaluation of bone seekers?
Mitterhauser M; Tögel S; Wadsak W; Mien LK; Eidherr H; Wiesner K; Viernstein H; Kletter K; Dudczak R
Bone; 2004 May; 34(5):835-44. PubMed ID: 15121015
[TBL] [Abstract][Full Text] [Related]
35. Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice.
Elgqvist J; Bernhardt P; Hultborn R; Jensen H; Karlsson B; Lindegren S; Warnhammar E; Jacobsson L
J Nucl Med; 2005 Mar; 46(3):464-71. PubMed ID: 15750160
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of 99mTc-MAG3-annexin V: influence of the chelate on in vitro and in vivo properties in mice.
Vanderheyden JL; Liu G; He J; Patel B; Tait JF; Hnatowich DJ
Nucl Med Biol; 2006 Jan; 33(1):135-44. PubMed ID: 16459269
[TBL] [Abstract][Full Text] [Related]
37. Yttrium-90-EDTMP: a radiotherapeutic agent in the treatment of leukaemias.
Keeling AA; Vaughan AT; Beaney RP
Br J Cancer; 1989 Jul; 60(1):74-8. PubMed ID: 2803919
[TBL] [Abstract][Full Text] [Related]
38. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.
Shen S; Forero A; LoBuglio AF; Breitz H; Khazaeli MB; Fisher DR; Wang W; Meredith RF
J Nucl Med; 2005 Apr; 46(4):642-51. PubMed ID: 15809487
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic effects of a 186Re-complex-conjugated bisphosphonate for the palliation of metastatic bone pain in an animal model.
Ogawa K; Mukai T; Asano D; Kawashima H; Kinuya S; Shiba K; Hashimoto K; Mori H; Saji H
J Nucl Med; 2007 Jan; 48(1):122-7. PubMed ID: 17204708
[TBL] [Abstract][Full Text] [Related]
40. Development of a rhenium-186-labeled MAG3-conjugated bisphosphonate for the palliation of metastatic bone pain based on the concept of bifunctional radiopharmaceuticals.
Ogawa K; Mukai T; Arano Y; Ono M; Hanaoka H; Ishino S; Hashimoto K; Nishimura H; Saji H
Bioconjug Chem; 2005; 16(4):751-7. PubMed ID: 16029015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
